Chronic use of hydroxychloroquine did not protect against covid-19 in a large cohort of patients with rheumatic diseases in brazil

Página do item simplificado
dc.creatorGecilmara Salviatopileggi
dc.creatorBlanca Bica
dc.creatorEloisa Duarte Bonfa
dc.creatorEduardo Ferreira Borba
dc.creatorDanielle Christinne Soares Egypto Brito
dc.creatorÂngela Luzia Branco Pinto Duarte
dc.creatorRafaela Cavalheiro Espírito Santo
dc.creatorPaula Reale Fernandes
dc.creatorMariana Peixoto Guimarães
dc.creatorKirla Wagner Poti Gomes
dc.creatorAdriana Maria Kakehasi
dc.creatorGilda Aparecida Ferreira
dc.creatorEvandro Mendes Klumb
dc.creatorCristina Costa Duarte Lanna
dc.creatorClaudia Diniz Lopes Marques
dc.creatorOdirlei André Monticielo
dc.creatorLicia Maria Henrique Mota
dc.creatorGabriela Araújo Munhoz
dc.creatorEduardo Santos Paiva
dc.creatorHelena Lucia Alves Pereira
dc.creatorJosé Roberto Provenza
dc.creatorSandra Lucia Euzébio Ribeiro
dc.creatorAna Paula Monteiro Gomides Reis
dc.creatorLaurindo Ferreira Rocha Junior
dc.creatorCamila Santana Justo Cintra Sampaio
dc.creatorVanderson Souza Sampaio
dc.creatorEmília Inoue Sato
dc.creatorThelma Skare
dc.creatorViviane Angelina de Souza
dc.creatorValeria Valim
dc.creatorMarcus Vinícius Guimarães Lacerda
dc.creatorRicardo Machado Xavier
dc.creatorMarcelo Medeiros Pinheiro
dc.creatorEdgard Torres Reis-neto
dc.creatorMirhelen Mendes Abreu
dc.creatorCleandro Pires Albuquerque
dc.creatorNafice Costa Araújo
dc.creatorAna Beatriz Bacchiega
dc.creatorDante Valdetaro Bianchi
dc.date.accessioned2024-01-18T20:52:19Z
dc.date.accessioned2025-09-08T23:34:18Z
dc.date.available2024-01-18T20:52:19Z
dc.date.issued2021
dc.format.mimetypepdf
dc.identifier.doi10.1186/s42358-021-00217-0
dc.identifier.issn25233106
dc.identifier.urihttps://hdl.handle.net/1843/63085
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofAdvances in Rheumatology
dc.rightsAcesso Aberto
dc.subjectCOVID‑19
dc.subjectHydroxycloroquine
dc.subjectRheumatic Diseases
dc.subject.otherCOVID‑19
dc.subject.otherHydroxycloroquine
dc.subject.otherRheumatic Diseases
dc.titleChronic use of hydroxychloroquine did not protect against covid-19 in a large cohort of patients with rheumatic diseases in brazil
dc.typeArtigo de periódico
local.citation.epage11
local.citation.issue60
local.citation.spage1
local.citation.volume61
local.description.resumoBackground: There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS‑CoV‑2 outbreak. Our aim was to compare the occurrence of COVID‑19 between rheumatic disease patients on hydroxychlo‑roquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil.Methods: This baseline cross‑sectional analysis is part of a 24‑week observational multi‑center study involving 22 Brazilian academic outpatient centers. All information regarding COVID‑19 symptoms, epidemiological, clinical, and demographic data were recorded on a specific web‑based platform using telephone calls from physicians and medical students. COVID‑19 was defined according to the Brazilian Ministry of Health (BMH) criteria. Mann–Whitney, Chi‑square and Exact Fisher tests were used for statistical analysis and two binary Final Logistic Regression Model by Wald test were developed using a backward‑stepwise method for the presence of COVID‑19.Results: From March 29th to May 17st, 2020, a total of 10,443 participants were enrolled, including 5166 (53.9%) rheumatic disease patients, of whom 82.5% had systemic erythematosus lupus, 7.8% rheumatoid arthritis, 3.7% Sjögren’s syndrome and 0.8% systemic sclerosis. In total,1822 (19.1%) participants reported flu symptoms within the 30 days prior to enrollment, of which 3.1% fulfilled the BMH criteria, but with no significant difference between rheumatic disease patients (4.03%) and controls (3.25%). After adjustments for multiple confounders, the main risk fac‑tor significantly associated with a COVID‑19 diagnosis was lung disease (OR 1.63; 95% CI 1.03–2.58); and for rheumatic disease patients were diagnosis of systemic sclerosis (OR 2.8; 95% CI 1.19–6.63) and glucocorticoids above 10 mg/ day (OR 2.05; 95% CI 1.31–3.19). In addition, a recent influenza vaccination had a protective effect (OR 0.674; 95% CI 0.46–0.98). Conclusion: Patients with rheumatic disease on hydroxychloroquine presented a similar occurrence of COVID‑19 to household cohabitants, suggesting a lack of any protective role against SARS‑CoV‑2 infection.
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE APARELHO LOCOMOTOR
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.initialsUFMG
local.url.externahttps://doi.org/10.1186/s42358-021-00217-0

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Chronic use of hydroxychloroquine did pdfa.pdf
Tamanho:
428.69 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG